2012
DOI: 10.1182/blood-2012-03-415356
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts

Abstract: The presence of > 15% bone marrow (BM) ring sideroblasts (RS) and < 5% blasts is required for a diagnosis of refractory anemia with ring sideroblasts. We examined the phenotypic and prognostic relevance of this "15%" RS threshold in 200 patients with myelodysplastic syndromes (MDS) without excess blasts and with > 1% RS. The impact of RS% was assessed both as a continuous and categorical variable: < 5% (n ‫؍‬ 56), 5%-14% (n ‫؍‬ 32), 15%-50% (n ‫؍‬ 79), and > 50% (n ‫؍‬ 33). RS% correlated (P < .

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
33
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
5
2

Relationship

4
3

Authors

Journals

citations
Cited by 70 publications
(34 citation statements)
references
References 24 publications
1
33
0
Order By: Relevance
“…In the current study, the mutational frequencies were SF3B1285%, JAK2V617F-33%, ASXL1-29%, DNMT3A-13%, SETBP1-13%, and TET2-10%. As in other myeloid neoplasms with RS, the presence of SF3B1 mutations strongly correlated with the BM RS%, and did not independently impact survival [5,13,14].…”
Section: Discussionmentioning
confidence: 51%
“…In the current study, the mutational frequencies were SF3B1285%, JAK2V617F-33%, ASXL1-29%, DNMT3A-13%, SETBP1-13%, and TET2-10%. As in other myeloid neoplasms with RS, the presence of SF3B1 mutations strongly correlated with the BM RS%, and did not independently impact survival [5,13,14].…”
Section: Discussionmentioning
confidence: 51%
“…Several recent studies have corroborated the correlation of the presence of SF3B1 mutations with bone marrow RS and suggest that MDS with RS has a favorable prognosis regardless of the presence of multilineage dysplasia [8,32,33]. Based on data from these studies, patients with MDS and SF3B1 mutation will be classified as either RARS or RCMD-RS based on the mere presence of RS regardless of the percentage of the RS [34]. Additionally, in the proposed revised classification, RCMD-RS will be recognized as a separate entity while RCMD and RCMD-RS were merged in the WHO 2008 classification.…”
Section: Introductionmentioning
confidence: 98%
“…SF3B1 mutations have a high prevalence ( 80%) in MDS and ring sideroblasts (RS) and do not influence either OS or leukemiafree survival (LFS) [15,16]. Similarly, these mutations are seen in a small fraction (<10%) of patients with primary myelofibrosis (PMF), are strongly associated with the presence of BM RS, but do not affect disease outcome [17].…”
Section: Introductionmentioning
confidence: 99%